Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 913-915

  Darda Bayraktar, Ulas ^a,b   Calzadilla Domingo, Gelenis ^a   Schmit, Jessica ^a   Pereira, Denise ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD33 ANTIGEN; CLOFARABINE; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPERTENSIVE CRISIS; HYPERTRANSAMINASEMIA; LEUKEMIA RELAPSE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REFRACTORY ACUTE MYELOID LEUKEMIA; RELAPSED ACUTE MYELOID LEUKEMIA; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; YOUNG ADULT;

EID: 79955057559     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.551570     Document Type: Article

References (8)

1. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-1727. (Pubitemid 34874002)
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
3. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.
4. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-1452. (Pubitemid 41356159)
5. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114(Suppl. 1): Abstract 790.
6. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49:2141-2147.
7. Nand S, Godwin J, Smith S, et al. Azacitidine plus gemtuzu-mab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly. Blood 2006;108(Suppl. 1): Abstract 1981.
8. Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 2009;84:599-600.